Disclosure of competing financial interests and role of sponsors in phase III cancer trials

This publication has 31 references indexed in Scilit:

• Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
  Annals of Oncology, 2002
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
  The Lancet, 2002
• Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
  British Journal of Cancer, 2002
• Declaring financial competing interests: survey of five general medical journals
  BMJ, 2001
• Uneasy Alliance — Clinical Investigators and the Pharmaceutical Industry
  New England Journal of Medicine, 2000
• Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer
  British Journal of Cancer, 1999
• Uniform Requirements for Manuscripts Submitted to Biomedical Journals
  Annals of Internal Medicine, 1997
• Ethics issues in academic-industry relationships in the life sciences
  Academic Medicine, 1996
• Understanding Financial Conflicts of Interest
  New England Journal of Medicine, 1993
• Conflict of interest
  The Lancet, 1993